Dave Inc has received a positive boost as Citizens has raised its stock price target from $300 to $310. This adjustment reflects growing confidence in the company's performance and potential for future growth, which is great news for investors looking for promising opportunities in the market.

Citizens has lowered its price target for BioCryst Pharma to $25, reflecting concerns about the company's outlook on hereditary angioedema (HAE). This adjustment is significant as it indicates potential challenges for BioCryst in meeting market expectations, which could impact investor confidence and the company's future growth prospects.

Citizens has reaffirmed its Market Outperform rating on Abivax stock, setting a target price of $114. This endorsement is significant as it reflects confidence in Abivax's potential for growth and success in the market, which could attract more investors and boost the company's stock performance.

Citizens has initiated coverage on Kalaris with a Market Outperform rating and set a price target of $20. This is significant as it reflects confidence in Kalaris's potential for growth and profitability, which could attract investors looking for promising opportunities in the stock market.

Citizens has initiated coverage on EZCORP stock, giving it a Market Outperform rating. This is significant as it suggests that Citizens believes EZCORP has strong potential for growth, which could attract more investors and positively impact the stock's performance. Investors often look to analysts' ratings to guide their decisions, and this endorsement could lead to increased interest in EZCORP.